chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I had one dose only in 2018; This case was reported by a consumer and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received in 2018).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: The reporter was the patient. The age at vaccination was not applicable for this report. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination. The reporter asked should  now start over and get both doses.
Shortness of breath, Wheezing, Hives, all with in 25 minutes.  Gave albuterol in the office via SVN machine and Benadryl IM.  Transported to ED via Ambulance.
patients have been administered doses while the temperature excursion assessment was ongoing; patients have been administered doses while the temperature excursion assessment was ongoing; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing) and EXPIRED PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing) and EXPIRED PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing) and EXPIRED PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication of the patient was not reported.  The reporter mentioned that the patient had been administered dose while the temperature excursion assessment was ongoing. The reporter also reported that, no adverse reactions were reported by the patient.  No treatment information was provided by the reporter.
Patient stated that the evening following her 1st dose (several hours later) she started with diarrhea and vomiting. It lasted for about 3 days. She treated diarrhea with Imodium. She did not see her doctor for the symptoms. Patient received dose as a leakage dose.
This case was reported by a nurse via call center representative and described the occurrence of fever in a female patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, unknown after receiving SHINGRIX, the patient experienced fever, pain in arm, swelling arm, nausea, vomiting and general body pain. On an unknown date, the outcome of the fever, pain in arm, swelling arm, nausea, vomiting and general body pain were unknown. It was unknown if the reporter considered the fever, pain in arm, swelling arm, nausea, vomiting and general body pain to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient experienced fever, arm swelling and pain, nausea, vomiting, and body aches after receiving SHINGRIX. The health care professional was not at her office and could not provide full patient details or lot number and expiration date of the product.
Patient reported of itchiness under the site of injection, about couple hours after received the injection. The redness appeared to be larger at the injection site. The symptoms don't seem to get better. Recommended patient to take BENADRYL to see if it would help with itchiness. If the symptom doesn't get better or get worse go to the doctor. If trouble breathing, throat swelling, dizziness or fainting go to the E.R.
Headache, Myalgia,  HA, Arm and Muscle aches Narrative:   Other Relevant History:
Patient presented to pharmacy with excessive redness of upper arm below the injection site spreading to forearm; interestingly, there was no apparent redness around the injection site.
Woozy, high fever (100-102), body aches, chills, headache, congestion, joint pain, blurry eyesight, lethargy, pain at injection site.
Spasms in left arm; Went to ER bc I thought it was a seizure; This is a spontaneous report from a contactable consumer. A 65-year-old non-pregnant female patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) at the age of 65 years, via an unspecified route of administration, administered in Arm Left on 20Jan2021 (Batch/Lot Number: EL3247) as a single dose for covid-19 immunization. Medical history included cancer from an unknown date and unknown if ongoing. Concomitant medications included levetiracetam (KEPPRA); mesalamine; prednisone; and folic acid, all taken for an unspecified indication, start and stop date were not reported. In Jan2021, the patient experienced spasms in left arm  and went to ER because she thought it was a seizure.  The patient was hospitalized due to the events for 2 days.  The patient underwent lab tests and procedures which included negative test for Covid-19 on 26Mar2021. The outcome of the events was recovered with sequelae
20 hours post vax, the pt had a fever of 100. 72 hours post vax, the pt arrived unresponsive to ER and died during resuscitative efforts. A blood culture grew pneumococcus. Child was status post stage I surgery for hypoplastic left heart syndrome.
not feeling good; feeling weak; Chills; hurt like someone hit her; feeling real thirsty; like she was going to pass out; Fever; Nausea; tingling on her face; This is a spontaneous report from a contactable consumer (patient). A 53 years old female patient received bnt162b2 (Pfizer-BioNTech COVID-19 mRNA vaccine, Lot Number EL3248 and Expiration Date Apr2021) via Intramuscular on 14Jan2021 (vaccine location: Left arm) at single dose for COVID-19 immunisation. The patient's ongoing medical history heart murmur and high blood pressure diagnosed about 10 years ago. The concomitant medications was reported as none. Patient was still not feeling good. She said that she had side effects that started on Saturday 16Jan2021. Caller clarified that she had fever, nausea, and tingling on her face. Fever was noticed it on Saturday 16Jan2021 and gone by about 2am on Sunday 17Jan2021. Patient stated that she was feeling real thirsty. Nausea was still there and this morning, patient felt like she was going to pass out. She stated that she had weakness. She stated that she is trying to make an appointment to see her doctor. She stated that the nausea is persisting, but the nausea comes and goes. She stated that yesterday she felt ok, but this morning, she felt nauseated and like she was going to pass out.  Patient said that the tingling stopped around 17Jan2021 02:00 along with the fever. Patient stated that she is drinking Gatorade and eating crackers and is staying stay hydrated. She stated that she is at work, but she feels weak. She stated that she had chills and she hurt like someone had hit her. She noticed these symptoms on Saturday 16Jan2021 and stated that this was ongoing and they come and go. The outcome of fever and tingling on her face was recovered on 17Jan2021 02:00. The outcome of not feeling good and feeling real thirsty was unknown. The outcome of other events was not recovered.
Itchy rash, hives. Reported to ER and was treated with steroid injections which helped. Then he was given Zantac and Atarax in clinic.
Patient had the typical fever/fatigue/body ache/fever  But then developed a severe case of ophthalmic  zoster about 5 days later
One day after receiving the vaccine I ended up at ER with a fever, severe migraine, and could barely stand up because I was extremely weak. They treated it with a steroid shot, benadryl, and Zofran. 2 months later I stopped having periods all together. I'm waiting for an appt. with my gynecologist to see what effects it may have caused and how to treat it if we can. Being that I'm 30 and my husband and I were trying for children this has put a hold on everything.
She received the vaccine on 14 Oct 06 at apporoximatley 1030.  By 1700 she was feeling dizzy and had the chills.  Her temperature at that time was 101.  She had a fever for the next 24 hours and the highest it got was 102.6.  She took ibuprofen to aleviate the fever, but it only helped her joint pain.  She then took Tylenol and her fever came down.
1st 24 hrs-72 hrs high fevers 103-104 degrees with TYLENOL. Constant crying, lethargic: continued spotting fevers through next 2-3 weeks, staring blankly, shaking head, crying, screaming. Lost all speech of aprx 50-70 words, started screaming a lot. Did not use speech again until 3 1/2 years-echolalia diagnosed autism age 5 yrs.
Burning in the chest. Face swollen and burning, lower part of face and neck still red, swollen and burning.  Nerve tingling
approx 1hr p.vax t103 ax w/c/o h/a;25SEP96 @ 10AM hives face, upper extremities-duration about 3hr-given DPH;no problems later;
PSA has flared; Knees are constantly swollen; This is a spontaneous report from a contactable consumer (patient). A 58-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 2 via an unspecified route of administration on 16Aug2021 (Lot Number: FC3180) at age of 58-year-old as DOSE 2, SINGLE for COVID-19 immunization.  Medical history included Psoriatic arthritis (PSA) (Humira is not effective anymore). There were no concomitant medications. No other vaccine in four weeks and no other medications in two weeks. Historical vaccine included first dose of COVID19 Vaccine (dose brand name unknown) for COVID-19 immunization. Since receiving vaccine, his PSA has flared. Humira was not effective anymore. Knees were constantly swollen after years of being under control with Humira. No covid prior vaccination. No covid tested post vaccination. No known allergies. The outcome of the events was not recovered.  No follow-up attempts are possible. No further information is expected.
Severe headache; Nausea; diarrhea; sore throat; cough; Muscle pain in arm; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 05Apr2021 at 16:00 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and the patient had an unspecified allergy. Concomitant medications included losartan (MANUFACTURER UNKNOWN) and hydrochlorothiazide (MANUFACTURER UNKNOWN), both taken from unknown dates. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021 at 16:00, immediately after the shot was administered, the patient experienced severe headache that had lessened slightly over the next few days. On 05Apr2021, the patient experienced nausea, diarrhea, sore throat, cough and muscle pain in arm for first 48 hours after the shot. Therapeutic measures were not taken as a result of the events. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the events nausea, diarrhea, sore throat, cough and muscle pain in arm were resolved on 07Apr2021, while that of severe headache was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Slight redness of the skin near the injection site. Itchy and sore, especially to the touch.
no adverse effects reported; patient was vaccinated with improperly stored MMR II; This spontaneous report has been received from a medical assistant, concerning a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not provided.  On 01-MAY-2019, the patient was vaccinated with improperly stored dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) (albumin status rHA) one dose, lot # R024906 with expiration date 30-AUG-2020 (frequency, route and anatomical location were not provided) which was reconstituted with sterile diluent (dose, frequency, route, lot number and expiration date were not provided) for prophylaxis. No adverse effects reported.  The temperature and time frame were unknown by reporter. There was previously temperature excursions and digital data logger was involved.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1906USA011469: US-009507513-1907USA010301: US-009507513-1907USA010302: US-009507513-1907USA010303: US-009507513-1907USA010304: US-009507513-1907USA010305: US-009507513-1907USA010306: US-009507513-1907USA010307: US-009507513-1907USA010308: US-009507513-1907USA010309: US-009507513-1907USA010310: US-009507513-1907USA010311: US-009507513-1907USA010312: US-009507513-1907USA010313: US-009507513-1907USA010314: US-009507513-1907USA010315: US-009507513-1907USA010316: US-009507513-1907USA010317: US-009507513-1907USA010318: US-009507513-1907USA010319: US-009507513-1907USA010320: US-009507513-1907USA010321: US-009507513-1907USA010322: US-009507513-1907USA010323: US-009507513-1907USA010324: US-009507513-1907USA010325: US-009507513-1907USA010326: US-009507513-1907USA010327: US-009507513-1907USA010328: US-009507513-1907USA010329: US-009507513-1907USA010330: US-009507513-1907USA010331: US-009507513-1907USA010332: US-009507513-1907USA010333: US-009507513-1907USA010334: US-009507513-1907USA010335: US-009507513-1907USA010336: US-009507513-1907USA010337: US-009507513-1907USA010338: US-009507513-1907USA010339: US-009507513-1907USA010340: US-009507513-1907USA010341: US-009507513-1907USA010342: US-009507513-1907USA010343: US-009507513-1907USA010344: US-009507513-1907USA010345: US-009507513-1907USA010346: US-009507513-1907USA010347: US-009507513-1907USA010348: US-009507513-1907USA010349: US-009507513-1907USA010350: US-009507513-1907USA010351: US-009507513-1907USA010352: US-009507513-1907USA010353: US-009507513-1907USA010354: US-009507513-1907USA010355: US-009507513-1907USA010356: US-009507513-1907USA010357: US-009507513-1907USA010358: US-009507513-1907USA010359: US-009507513-1907USA010360: US-009507513-1907USA010361: US-009507513-1907USA010362: US-009507513-1907USA010364: US-009507513-1907USA010365: US-009507513-1907USA010366: US-009507513-1907USA010367: US-009507513-1907USA010368: US-009507513-1907USA010369: US-009507513-1907USA010370: US-009507513-1907USA010371: US-009507513-1907USA010372: US-009507513-1907USA010373:
This spontaneous report as received from a pharmacist refers to a male patient of unknown age with a history of allergies and no unknown drug reactions. On unspecified date, the patient was vaccinated with ZOSTAVAX (dose and lot not provided). No concomitant medications were reported. The pharmacist stated that on unspecified date, the patient who was administered ZOSTAVAX at the pharmacy on an unspecified date, developed redness and swelling at the injection site, the patient sought medical attention by calling the pharmacist and he did not received medication and did not performed laboratory tests, subsequently the injection site reaction resolved in 4 days without requiring treatment. The relatedness for redness and swelling at the injection site was unknown for ZOSTAVAX. Additional information has been requested.
Re VIVOTIF Berna EC Capsules- live oral vaccine for typhoid Ty21a: 59 year old man developed acute onset diplopia in all visual fields after taking the second of four oral doses of this attenuated vaccine. The diplopia was primarily vertical. Past medical history notable only for controlled hypertension, on metoprolol, diltiazem, and losartan. There was no history of prior neurological abnormalities, visual disturbances, head trauma, or intercurrent or recent illnesses. Neurology and neuro-ophthalmology consults were obtained. Neurological exam was normal apart from diplopia. Brain MRI was unremarkable. Blood tests were unremarkable. Diagnosis by neuro-ophthalmologist was fourth cranial nerve palsy. After two weeks the patient (a physician) self-prescribed a 6-day steroid taper. Diplopia began to slowly improve after this, although it is uncertain to what extent steroids contributed. After two months the diplopia was restricted to far right gaze, and by 3.5 months the diplopia had completely resolved. The temporal relationship to taking this oral vaccine strongly suggests an adverse immunological response to the medication.
Headache.  18 hours after shot to 35 hours after shot. Went to bed for 11 hours. Overall achiness. 18 hours after shot to 35 hours after shot. Went to bed for 11 hours. Axillary lymphadenopathy. 36 hours after shot and continuing. No treatment.
Cluster seizures and significant vomiting. Occured sporadically until 9:00 am next morning (10/13/2010). Went to medical center at 9:00 pm on 10/12/2010. Remained in hospital and was admitted at 9:00 am 10/13.  Remained in the hospital until the evening of 10/14/2010.  Had never had seizures following vaccines previously.
rash on arm; covid arm; This spontaneous case was reported by a consumer and describes the occurrence of RASH (rash on arm) and VACCINATION SITE REACTION (covid arm) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029L20A and 030M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (no medical history provided).   On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 11-Jan-2021, the patient experienced RASH (rash on arm) and VACCINATION SITE REACTION (covid arm). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE, ZINC ACETATE (BENADRYL ITCH STOPPING CREAM) for Rash, at an unspecified dose and frequency. At the time of the report, RASH (rash on arm) and VACCINATION SITE REACTION (covid arm) outcome was unknown.
PT WAS UNKNOWINGLY ADMINISTERED 0.2 ML OF UNDILUTED VACCINE. NO ADVERSE EFFECTS REPORTED DURING OBSERVATION PERIOD... FOLLOW UP THE NEXT MORNING (11/15) ALSO SHOWED PT OK, MOTHER REPORTS ONLY ARM SORENESS AS EXPECTED. FURTHER FOLLOW UP WILL BE MADE.  THIS REPORT IS REGARDING AN ADMINISTRATION ERROR, NOT AN ADVERSE REACTION
Incorrect dose administered for dose 2 following CDC guidelines discontinued monovalent.  Dose administered 0.2ml/10ug Pink cap/yellow label.
no adverse event; patient received unspecified dose in VARIVAX immuniz.ation series that was improperly stored; This spontaneous report was received from a nurse and refers to a 4 years old patient. Information regarding the patient's medical history, concurrent conditions and concomitant medications was not provided.     On 09-JUL-2020, the patient was vaccinated with unspecified improperly stored dose of varicella virus vaccine live (oka/merck)(VARIVAX) lot # S038178 with expiration date of 26-NOV-2021 for prophylaxis. No symptoms or additional adverse effects reported. The vaccine experienced temperature of excursión of 67 degrees Fahrenheit for 17 hours. There were not previous excursion, Digital data logger was involved.
On 10/24/00 a telephone call from the parent stating the pt had a red area at the left thigh measuring 2 1/2". On 10/25/00, called the parent to check on status of pt. the area was larger and warm. Advised to return to the clinic for evaluation. The left thigh was red and swollen with a 4" area noted.
leaked out of injection site; Tired; nausea; headache; A spontaneous report was received by a health care professional concerning a female patient of an unknown age, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced felt tired, nausea, headaches and after the shot some of the dose leaked from the injection site.  The patient's medical history was not provided by the reporter. Concomitant product use was not reported.  On 26 Dec 2020, prior to the onset of the events, the patient received first dose of mRNA-1273 (Lot number unknown) for prophylaxis of COVID-19 infection. After first dose the patient experienced nausea, headache, and felt tired.  On an unknown date, the patient received second dose of mRNA-1273 (Lot number unknown). After second dose the patient developed no reaction at all, but some of the dose leaked out of the injection site.  Action taken with mRNA-1273 in response to the events was not reported.  The outcomes of the events felt tired, nausea, headaches, and after the shot some of the dose leaked from the injection site were unknown.; Reporter's Comments: This report refers to a case of dose leaked out of the injection site for mRNA-1273, lot # unknown. Based on the current available information and temporal association between the use of the product and the onset of the events, a causal relationship cannot be excluded.
Chest and throat tightness minutes after vaccination - was given epinephrine subcutaneously and anadryl and solumedrol and pepan and zyrtec.
Pt started showing sign of redness to leg about then size of quarter that progress to size of grapefruit on 19APR94; pt seen 20APR94 area was red hard area;
Moderate lymphedema on right side neck(supraclavicular/ lower cervical) / armpit and mild left supraclavicular  first few weeks after vaccination. Continued / current lymphedema right  neck. . Fills and drains throughout the day depending on body positioning.
Rash on arm severe headache given Benadryl toradol and observation had a second episode possibly related to vaccine of throat swelling on 1/23/21 treated same but added steroid injection
Arthralgia, Fever, Fatigue, Chills Narrative:  Other Relevant History:
Vomiting & nausea - 2 days (48 hours after first dose) Vomiting & nausea - 3 hours after 2nd dose
Patient experienced loss of vision, trouble walking, and developed shingles as an immune response. The patient did not report the manufacturer or dates of vaccine.
Information has been received from the mother of a 19 year old female consumer who in early January 2008, was vaccinated with the first dose of GARDASIL (lot not reported), In later February 2008 the patient was vaccinated with the second dose of GARDASIL (lot not reported). There was no concomitant medication. In January 2008, the patient began to experience depression and a feeling of "just not being herself with no known reason". Two weeks after her second dose of GARDASIL (lot not reported), she experienced a panic attack. Her current condition was described as resembling a "hormonal mood swing reaction." There does not seem to be an explanation for these feelings. She experienced these feeling away at college as well as at home. She is being seen by a physician and has an upcoming appointment in early May 2008 for these symptoms. The patient's status was reported as not recovered. No further information is available.
Patient complained of itching at 12:55 pm on both arms while in Observation site.   EMS at bedside. EKG showed NSR. No symptoms of SOB, difficulty breathing.  VS 179/96; HR 64; O2 Sat 98 on Room Air. Temp 95.4 Patient awake/alert x3/ following commands.  Benadryl 25mg  po administered per AP @ 1304.  Resolution of symptoms  at 1310.